Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
about
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumorsSuperior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivityA universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.Recent advances in targeted therapy of human myelogenous leukaemia.A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.Current status and future prospects for anti-angiogenic therapies in cancer.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapyHepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases.A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor.Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
P2860
Q28292264-6D1841B9-1DE8-4CF5-B72B-833B647ED547Q28729760-8813DD21-B1EA-4F21-AB8F-8BC08F7B0E07Q34104980-F80A45FA-22E8-4B25-9B35-5C5FB27FF393Q36302860-38CB8163-E9F4-4B26-A8F3-0435445FB9A8Q36318531-C6AB4D5B-151C-423B-BB60-FA0CB0AD03D9Q36642955-C256500E-F0BB-4153-A80F-42A0D7960E5CQ36920799-4F0B3007-BD3D-44FF-941E-D5A319487DBBQ38088366-E0BDF555-8BB7-425E-9E84-648DDC85A669Q39579889-CE2DD5CA-9104-49A5-BB3C-BA48B4B284A8Q40219057-40765054-92CB-4B73-815D-2C4F6869A3E5Q41129245-D65D5520-C4D9-4059-B5E5-172447043E08Q44740671-177FF33A-C0B4-43FE-9E4B-A54C9A220202Q48589913-1ABAA0E0-9C10-4267-8761-678DB6AEF492Q58751938-98578742-136F-4BFC-A64B-27857F1632AA
P2860
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@ast
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@en
type
label
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@ast
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@en
prefLabel
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@ast
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@en
P2860
P1476
Cetuximab (Erbitux)--an emergi ...... r receptor-expressing tumours.
@en
P2093
P2860
P304
P356
10.1111/J.1368-5031.2004.00369.X
P577
2004-10-01T00:00:00Z